REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.77
+0.56%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +15.9%
- EBIT
- +15.9%
- EPS
- +22.5%
- Free cash flow
- +8.9%
- Operating cash flow
- +6.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +30.3%
- EPS
- +33.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -17.9%
- EBIT
- -22.3%
- Net income
- -26.9%
- EPS
- -10.1%
- Free cash flow
- -43.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026